Real‑world and clinical data reaffirm that the CFTR modulator combination elexacaftor/tezacaftor/ivacaftor (ETI) delivers measurable clinical benefits in pediatric cystic fibrosis patients. The report highlights improved lung function and symptomatic endpoints in children, extending the therapy’s established efficacy profile beyond adults. These findings support expanded use of ETI in younger age groups and may influence label adjustments, payer access and early‑intervention strategies. CFTR modulators continue to reshape standards of care by targeting the underlying defect rather than downstream sequelae. Longer‑term follow‑up will be needed to quantify sustained benefits, growth and safety in younger cohorts as regulators and clinicians weigh broader pediatric adoption.